Jianpi Huoxue Recipe in Treating Gastric Premalignant Lesion

Gastric Precancerous Condition Clinical Trial

Official title:

Therapeutic Mechanism of Jianpi Huoxue Recipe in Treating Gastric Premalignant Lesion：A Multi-center, Randomized and Controlled Experiment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03823248
• Other study ID #: 2017YFC1700601
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 1, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: June 2021
• Source: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Contact: Xiangxue Ma, Doctor
• Phone: +86(010)62835641
• Email: maxiangxue[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study had adopted the multi-center, randomized and controlled experiment design based on standardized mucosal biopsy and pathohistological operation, as well as therapeutic evaluation methodology. Meanwhile, patients diagnosed with chronic atrophic gastritis accompanying with low grade intraepithelial neoplasia and indefinite dysphasia (grade C2/C3 of Vienna classification) confirmed by gastroscopic histopathology were enrolled as the objects of study, while folic acid was used as the control. The therapeutic effect and safety of Jianpi Huoxue Recipe (Moluodan + Sanchi powder) in intervening the gastric Premalignant lesion were evaluated from the points of view of pathology, gastroscopy and symptoms. The elimination rate of intraepithelial neoplasia of gastric mucosa was expected to be improved by 9-12%. Moreover, high quality evidence-based medical evidence regarding traditional Chinese medicine (TCM) in intervening gastric Premalignant lesion would be obtained, which could form the mature, propagable and effective scheme.

Description:

Intraepithelial neoplasia of gastric mucosa is a well-recognized gastric Premalignant lesion, which is the key of secondary prevention for gastric cancer. However, no universally acknowledged effective therapeutic scheme is available at present. Previously, the investigator's research group has carried out clinical trial study based on solving the key problems such as diagnostic criteria, mucosal biopsy consistency and therapeutic evaluation methodology, and has attained certain achievements. This study had adopted the multi-center, randomized and controlled experiment design based on standardized mucosal biopsy and pathohistological operation, as well as therapeutic evaluation methodology. Meanwhile, patients diagnosed with chronic atrophic gastritis accompanying with low grade intraepithelial neoplasia and indefinite dysphasia (grade C2/C3 of Vienna classification) confirmed by gastroscopic histopathology were enrolled as the objects of study, while folic acid was used as the control. The therapeutic effect and safety of Jianpi Huoxue Recipe (Moluodan + Sanchi powder) in intervening the gastric Premalignant lesion were evaluated from the points of view of pathology, gastroscopy and symptoms. The elimination rate of intraepithelial neoplasia of gastric mucosa was expected to be improved by 9-12%. Moreover, high quality evidence-based medical evidence regarding traditional Chinese medicine (TCM) in intervening gastric Premalignant lesion would be obtained, which could form the mature, propagable and effective scheme. At the same time, molecular and biological indicators, including CDX2, SOX2, MUC2, MUC6, MUC5AC and CD10, were detected using the pathological tissues, so as to explore the therapeutic mechanism of Jianpi Huoxue Recipe in intervening gastric Premalignant lesion, and to construct the model platform for special disease research on gastric Premalignant lesion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 480
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Outpatients and inpatients diagnosed with chronic atrophic gastritis accompanying with low grade intraepithelial neoplasia and indefinite dysphasia confirmed by gastroscopy and histopathological examination;

2. Patients aged from 18-75 years;

3. Subjects who were informed and voluntarily signed the informed consent.

Exclusion Criteria:

1. Patients pathohistologically diagnosed with high grade intraepithelial neoplasia/severe dysplasia;

2. Patients with a history of gastric ulcer, gastric polyps and gastric surgery;

3. Patients taking NSAIDs for a long term;

4. Patients suspected of gastric cancer or malignant lesions in other systems;

5. Patients with a history of gastric surgery;

6. Patients with concurrent primary diseases in cardiovascular, cerebrovascular, liver, kidney and hemopoietic systems (ALT>80 u/L, and/or AST>80 u/L, with abnormal renal function)

7. Patients with mental disease, dysgnosia and logopathy;

8. Pregnant women, or those preparing a pregnancy and breastfeeding women;

9. Patients with a allergic history of medicines used in this experiment.

Related Conditions & MeSH terms

• Gastric Precancerous Condition
• Precancerous Conditions

Intervention

Drug:
• MoLuoDan
oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
• Sanchi powder
oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
• Folic Acid Tablet
oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
• MoLuoDan simulation
oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
• Sanchi powder simulation
oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
• Folic Acid Tablet simulation
oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.

Locations

Country	Name	City	State
China	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Beijing

Sponsors (9)

Lead Sponsor

Collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijing Friendship Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital of KUNSHAN, Wuhan Integrated Traditional Chinese and Western Medicine Hospital, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The disappearance rate of dysplasia	The all patients' histopathology will be evaluated two times, the first time is when the patients' are included into the clinical trials, the second time is after 24 weeks treatment in each group, patients' histopathology should be evaluated for comparison between two groups,at the same time patients' histopathology should be evaluated for comparison in each group.The change in histological score (mean score of all biopsie after treatment in each group and between groups was calculated. The response rate of each pathological lesion was calculated as a percentage of those improved or disappeared at the 6th month to all subjects. The disappearance rate of dysplasia between groups were compared, which was defined as the absence of dysplasia (score 0) in all biopsy specimens after treatment.	six months
Primary	The score changes of histopathology	The score changes of atrophy, intestinal metaplasia, chronic inflammation and active inflammation compared between baseline and after 6-month treatment.	six months
Secondary	The score changes of Endoscopic Findings	The score changes of endoscopic findings, such as erosion, bleeding, coarse and uneven mucosa, and bile reflux were compared between baseline and after 6-month treatment.	six months
Secondary	Main symptom score	Changes of symptom score were compared. The symptom include upper abdominal pain, upper abdominal distension, poor appetite, nausea and belching. The disappearance rate of symptom was expressed as a percentage of the subjects whose symptoms disappeared after medication to those exhibiting symptoms before medication.	six months
Secondary	The patient-reported outcome (PRO)scale integrals	The patient-reported outcome (PRO) instrument for chronic gastrointestinal diseases was a 35-item instrument, including 6 dimensions of regurgitation, dyspepsia, defecation, general condition, emotion and social function. All items graded into 5 levels and scored 0-4, except for decreased appetite, which is grouped into 4 levels and scored 0-3.	six months